GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carl Zeiss Meditec AG (OTCPK:CZMWY) » Definitions » Debt-to-EBITDA

CZMWY (Carl Zeiss Meditec AG) Debt-to-EBITDA : 0.48 (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Carl Zeiss Meditec AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Carl Zeiss Meditec AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $27 Mil. Carl Zeiss Meditec AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $141 Mil. Carl Zeiss Meditec AG's annualized EBITDA for the quarter that ended in Sep. 2024 was $350 Mil. Carl Zeiss Meditec AG's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 0.48.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Carl Zeiss Meditec AG's Debt-to-EBITDA or its related term are showing as below:

CZMWY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03   Med: 0.23   Max: 0.56
Current: 0.56

During the past 13 years, the highest Debt-to-EBITDA Ratio of Carl Zeiss Meditec AG was 0.56. The lowest was 0.03. And the median was 0.23.

CZMWY's Debt-to-EBITDA is ranked better than
67.98% of 431 companies
in the Medical Devices & Instruments industry
Industry Median: 1.54 vs CZMWY: 0.56

Carl Zeiss Meditec AG Debt-to-EBITDA Historical Data

The historical data trend for Carl Zeiss Meditec AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carl Zeiss Meditec AG Debt-to-EBITDA Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.30 0.27 0.31 0.38

Carl Zeiss Meditec AG Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 - 0.47 - 0.48

Competitive Comparison of Carl Zeiss Meditec AG's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carl Zeiss Meditec AG's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Debt-to-EBITDA falls into.



Carl Zeiss Meditec AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Carl Zeiss Meditec AG's Debt-to-EBITDA for the fiscal year that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(27.292 + 140.685) / 447.349
=0.38

Carl Zeiss Meditec AG's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(27.292 + 140.685) / 350.232
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Carl Zeiss Meditec AG  (OTCPK:CZMWY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Carl Zeiss Meditec AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Carl Zeiss Meditec AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Carl Zeiss Meditec AG Business Description

Address
Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest medical technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.